Gregory Stampfli, MD
Family Medicine · Cheyenne, WYNPI 1174637359
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 104 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations.
Across 104 payments — averaging $18.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$337
- GSK$203
- Boehringer Ingelheim$171
- Pfizer$159
- Lilly USA, LLC$140
- Merck$118
- plus $790 from 19 others
What the payments were for
- Food & beverage$1,90299%
- Education$161%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 20 | $337 |
| GSK | 10 | $203 |
| Boehringer Ingelheim | 8 | $171 |
| Pfizer | 11 | $159 |
| Lilly USA, LLC | 10 | $140 |
| Merck | 7 | $118 |
| Boston Scientific | 2 | $117 |
| Novo Nordisk | 6 | $114 |
| Amgen | 6 | $101 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $71 |
| AbbVie(2 entities) | 2 | $70 |
| Phadia US Inc. | 3 | $50 |
| Exact Sciences | 2 | $33 |
| Corium, LLC | 2 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Dexcom, Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Alkermes, Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $18 |
| Novartis | 1 | $16 |
| Inspire Medical Systems, Inc. | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Viiv Healthcare Company | 1 | $12 |
How this compares
$1,918 in reported general payments places this provider in the 85th percentile of 237 family medicine providers in Wyoming.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 89 | $90,533 |
| TrulicityDulaglutide | 56 | $71,905 |
| JardianceEmpagliflozin | 52 | $62,734 |
| OzempicSemaglutide | 43 | $45,580 |
| XareltoRivaroxaban | 29 | $35,255 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $22,934 |
| Breo ElliptaFluticasone/Vilanterol | 35 | $16,061 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 27 | $15,346 |
| MounjaroTirzepatide | 12 | $13,053 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 28 | $3,551 |
| SynthroidLevothyroxine Sodium | 58 | $3,324 |
| Atorvastatin Calcium | 399 | $3,288 |
| LantusInsulin Glargine,hum.Rec.Anlog | 19 | $3,069 |
| GlyxambiEmpagliflozin/Linagliptin | 11 | $2,894 |
| Metoprolol Succinate | 178 | $2,335 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $159 | $90,53389 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $140 | $84,95868 claims |
| Boehringer IngelheimJardiance, Glyxambi | $171 | $65,62863 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $203 | $54,34194 claims |
| Novo NordiskOzempic | $114 | $45,58043 claims |
| Johnson & JohnsonXarelto | $18 | $35,25529 claims |
| AbbVieSynthroid | $70 | $3,32458 claims |
| Sanofi-aventis U.S. LLCLantus | $24 | $3,06919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 237 family medicine providers in Wyoming.
Other family medicine in Cheyenne
- Jonathon MedinaCheyenne$6K
- Carol FischerCheyenne$6K
- Douglas EdgrenCheyenne$5K
- Nancy BergquistCheyenne$3K
- Amy HarnishCheyenne$2K
- Joseph DobsonCheyenne$2K
- Samuel HartCheyenne$2K
- Aaron FreemanCheyenne$2K
- Patrick YostCheyenne$1K
- Kimberly BroomfieldCheyenne$971
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.